Data first, trial second: Rethinking evidence generation in rare disease
Rare-disease drug development has rarely been constrained by trial design; evidence design is the critical success factor. The current status quo encourages "phase 3 thinking in a phase 0 world." The moment a sponsor has a promising preclinical asset, teams begin debating randomization ratios and endpoints for a pivotal trial that may never be the most important source of evidence.
Instead, we must flip the paradigm. We should not ask, "What should our trial design look like?" We must ask, "What is the integrated evidence package required to convince regulators, payers, physicians, and patients that this treatment meaningfully changes lives?" In this new model, the clinical trial is just one piece of a broader data collection strategy.
Related Insights
Blog
FDA's revised effectiveness guidance: What it means for evidence strategy and real-world research
Oct 29, 2026
Article
A shifting European policy landscape: How will Europe’s new incentives reshape rare-disease clinical development?
Oct 26, 2026
Article
China’s rare disease drug development landscape: Overview and insights for global biopharmaceutical companies
Oct 22, 2026
Webinar
The evidence gap in hematology: From trial endpoints to patient outcomes
Oct 1, 2026
Case Study
Speed meets strategy: Delivering a critical FDA 1572 package in just seven days
Sep 9, 2026
Blog
Data without borders: Assessing China-only evidence for EMA approval – insights from ex-EMA and seasoned subject matter experts
Aug 19, 2026
Blog
Japan: the new strategic launchpad for accelerating global rare disease development
Jul 23, 2026
Blog
A Deep Dive into the Genetic Therapies Bootcamp at the ACMG 2026 Annual Meeting
Jun 23, 2026
Blog
Hope Interrupted: Why Even Short Gaps in Rare Disease Treatment Matter More Than We Think
Jun 23, 2026
Blog
Faster access for rare disease patients starts with smarter alignment
Jun 22, 2026
CTB Blog
Shaping a competitive, patient-centered future for Europe: Insights from the EURORDIS Round Table of Companies
Mar 5, 2026
Blog
Bolster your investor narrative with RWE
Jan 26, 2026
Related Insights
Blog
FDA's revised effectiveness guidance: What it means for evidence strategy and real-world research
Oct 29, 2026
Article
A shifting European policy landscape: How will Europe’s new incentives reshape rare-disease clinical development?
Oct 26, 2026
Article
China’s rare disease drug development landscape: Overview and insights for global biopharmaceutical companies
Oct 22, 2026
Webinar
The evidence gap in hematology: From trial endpoints to patient outcomes
Oct 1, 2026
Case Study
Speed meets strategy: Delivering a critical FDA 1572 package in just seven days
Sep 9, 2026
Blog
Data without borders: Assessing China-only evidence for EMA approval – insights from ex-EMA and seasoned subject matter experts
Aug 19, 2026
Blog
Japan: the new strategic launchpad for accelerating global rare disease development
Jul 23, 2026
Blog
A Deep Dive into the Genetic Therapies Bootcamp at the ACMG 2026 Annual Meeting
Jun 23, 2026
Blog
Hope Interrupted: Why Even Short Gaps in Rare Disease Treatment Matter More Than We Think
Jun 23, 2026
Blog
Faster access for rare disease patients starts with smarter alignment
Jun 22, 2026
CTB Blog
Shaping a competitive, patient-centered future for Europe: Insights from the EURORDIS Round Table of Companies
Mar 5, 2026
Blog
Bolster your investor narrative with RWE
Jan 26, 2026

